<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221209056758N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-01-01</date_registration>
      <primary_sponsor>Babol University of Medical Sciences</primary_sponsor>
      <public_title>Gho­­rs-Gol-Mohammadi in functional dyspepsia</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of‏‎ the poly-herbal preparation, “Gho­­rs-Gol-Mohammadi”, ‎on  clinical symptoms of patients with functional dyspepsia with H. pylori  infection: a ‎double-blind randomized controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-02-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67360</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: First, based on the computerized random number table, the statistical consultant provides a list of numbers to the person preparing the drugs. After completing the drug preparation process, in the labeling stage, the containers are coded according to the series of numbers, and the list of numbers and groups is kept confidentially by the person preparing the drug until the end of the study. Permuted blocks of 4  are used to randomly allocate participants in two interventions groups, and the preparations are placed in envelopes in the order of random allocation created, Blinding description: The participants, the main researcher, the health care personnel who are responsible for the care of the patients, as well as the statistical analyzer, are blinded to the allocation of the two intervention groups to the drug or placebo. In this way, they are not aware of random codes, random allocation method and product type. Both products are prepared with the same dosage form and are placed in the same completely sealed containers.</study_design>
      <phase>3</phase>
      <hc_freetext>Functional dyspepsia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention group: GHors-Golmohammadi tablet consisting of R. damascena petals and dried licorice and N. jatamansi rhizomes, with a dose of 500 mg, three times a day (after meals) for 4 weeks. The drug is prepared by a specialist pharmacist in the pharmacy laboratory of the Faculty of Traditional Medicine of Babol University of Medical Sciences. In order to prepare medicine, in  each plant is dried and ground into powder. Rose, licorice and jatamansi plant powders are mixed in a weight ratio of 2:1:1 and mixed with suitable excipients and natural polymers. Then, the powder is moistened and granulated for a short time by means of a certain ratio of wetting agents. After drying and disinfecting, the granules are ground again, then, tablets are pressed. The tablet is determined by the amount of gallic acid and glycyrrhizic acid, and physicochemical and microbial control tests are performed. Intervention 2: Control group:  placebo. 3 times a day, for 4 weeks. Both groups are received standard treatments. The placebo is prepared by a specialist pharmacist in the pharmacy laboratory of the Faculty of Traditional Medicine of Babol University of Medical Sciences. For the preparation of placebo, corn starch is used. In order to make its smell similar to the original medicine, it is mixed with the powder of Ghors-Gol-mohammadi at a ratio of 1%. Also, allowed and standard coloring agent is used to simulate the color of the original tablet. Each tablet contains 500 mg of powder. microbial limit tests are performed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nader Behgam</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>GanjAfrooz St</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4717647745</zip>
        <telephone>+98 11 3219 4728</telephone>
        <email>Behgam98@gmail.com</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zahra Memariani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>GanjAfrooz St</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4717647745</zip>
        <telephone>+98 11 3219 4728</telephone>
        <email>memarianiz@gmail.com</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with complaints of Functional dyspepsia
Diagnosis of functional dyspepsia based on ROME IV criteria by gastroenterologist
Helicobacter pylori infection positive test</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of peptic ulcer or reflux disease
Endoscopy with specific pathological findings
The presence of underlying diseases including heart failure, high blood pressure, kidney failure and uremic disease, cirrhosis
History of abdominal surgery
Any type of malignancy, history of chemotherapy and radiotherapy or exposure to radioactive radiation
Pregnancy and breastfeeding
Helicobacter pylori infection negative test
NSAIDs or any herbal medicine use
Smoking and alcohol consumption
History of any sensitivity to formulation components</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K30</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Functional dyspepsia</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention group: GHors-Golmohammadi tablet consisting of R. damascena petals and dried licorice and N. jatamansi rhizomes, with a dose of 500 mg, three times a day (after meals) for 4 weeks. The drug is prepared by a specialist pharmacist in the pharmacy laboratory of the Faculty of Traditional Medicine of Babol University of Medical Sciences. In order to prepare medicine, in  each plant is dried and ground into powder. Rose, licorice and jatamansi plant powders are mixed in a weight ratio of 2:1:1 and mixed with suitable excipients and natural polymers. Then, the powder is moistened and granulated for a short time by means of a certain ratio of wetting agents. After drying and disinfecting, the granules are ground again, then, tablets are pressed. The tablet is determined by the amount of gallic acid and glycyrrhizic acid, and physicochemical and microbial control tests are performed.</i_keyword>
      <i_keyword>Control group:  placebo. 3 times a day, for 4 weeks. Both groups are received standard treatments. The placebo is prepared by a specialist pharmacist in the pharmacy laboratory of the Faculty of Traditional Medicine of Babol University of Medical Sciences. For the preparation of placebo, corn starch is used. In order to make its smell similar to the original medicine, it is mixed with the powder of Ghors-Gol-mohammadi at a ratio of 1%. Also, allowed and standard coloring agent is used to simulate the color of the original tablet. Each tablet contains 500 mg of powder. microbial limit tests are performed.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The effect of «Ghors-Gol-mohammadi» on the severity of Functiona dyspepsia symptoms based on the total score of the GSRS questionnaire. Timepoint: At the beginning of the study, the second, fourth, sixth and eighth weeks from the beginning of the intervention. Method of measurement: Gastrointestinal Symptom Rating Scale questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The effect of "Ghors-Gol-mohammadi" on the severity of gastrointestinal symptoms in each of the 5 subgroups of symptoms of the Gastrointestinal Symptom Rating Scale questionnaire and the symptoms related to postprandial distress syndrome. Timepoint: Before starting the intervention, the second, fourth, and eighth following weeks. Method of measurement: Gastrointestinal Symptom Rating Scale.</sec_outcome>
      <sec_outcome>Score of quality of life. Timepoint: before the starting the intervention and at the eighth week. Method of measurement: Persian Nepean Quality of Life Questionnaire (NDI-10).</sec_outcome>
      <sec_outcome>Helicobacter pylori infection. Timepoint: Before the starting of the study and at the sixth week. Method of measurement: Urea breath test.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Babol University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-11-27</approval_date>
        <contact_name>Research Ethics Committee, Health Research Institute, Babol University of Medical Sciences</contact_name>
        <contact_address>GanjAfrooz St; Babol University of Medical Sciences, Babol Babol Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
